Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2017 | 06-2017 | 03-2017 | 12-2016 | 09-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 958 | 33 | 242 | 149 | 287 |
| TOTAL | $1,039 | $284 | $272 | $200 | $376 |
| Non-Current Assets | |||||
| PPE Net | 43 | 51 | 60 | 67 | 81 |
| Other Non-Current Assets | 5,510 | 5,510 | 5,510 | 5,540 | 6,556 |
| TOTAL | $5,553 | $5,561 | $5,570 | $5,607 | $6,637 |
| Total Assets | $6,591 | $5,845 | $5,842 | $5,807 | $7,013 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 109 | 192 | 109 | 194 | 145 |
| Accrued Expenses | 255 | 330 | 158 | 270 | 316 |
| Other current liabilities | N/A | 1,845 | 534 | 0 | 6 |
| TOTAL | $1,076 | $2,774 | $1,058 | $764 | $467 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 320 |
| TOTAL | $2,200 | $2,200 | $2,200 | $2,200 | $2,920 |
| Total Liabilities | $3,276 | $4,974 | $3,258 | $2,964 | $3,387 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 64 | N/A | 34 | 26 | 26 |
| Common Shares | 514 | 292 | 269 | 207 | 205 |
| Retained earnings | -123,206 | -121,824 | -119,454 | -117,379 | -116,573 |
| Other shareholders' equity | 0 | 2 | 2 | 2 | 2 |
| TOTAL | $3,315 | $871 | $2,585 | $2,842 | $3,626 |
| Total Liabilities And Equity | $6,591 | $5,845 | $5,842 | $5,807 | $7,013 |